SSR1

Across TCGA pan-cancer cohorts, SSR1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SSR1 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SSR1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SSR1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and COAD show a favorable association.

CCRCC, LUAD, and COAD are the cancer types where SSR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.650	0.957	.012	26	view →
LUAD	DFS	Tertile	All	0.996	0.823	.010	9	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
GBM	DFS	Median	All	0.276	0.440	.018	5	view →
OV	DFS	Quartile	All	1.000	0.591	.049	4	view →
UCEC	DFS	Median	II,III,IV	0.549	0.867	.046	4	view →
LSCC	DFS	Quartile	II,III,IV	0.304	0.776	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SSR1–CCRCC (OS)

Open the CCRCC breakdown →